The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR. 

Medtronic's third quarter included a boom in PFA sales and a significant investment in Anteris Technologies. CEO Geoff Martha said the company hopes to make an even bigger impact in the structural heart space as time goes on.

Researchers found that their advanced machine learning model consistently outperformed current risk stratification techniques.

Nearly 40 healthcare organizations signed a letter in support of the bipartisan legislation, noting that Medicare's “efficiency adjustment” decreases reimbursement during a challenging time for physicians.

The new technology synthesizes signals from a credit card-sized device into a 12-lead ECG representation. 

Mandates for universal ECG screening are gaining momentum as a way to combat the risk of SCA. However, the ACC warned, modern healthcare systems were not built to withstand such a rise in demand. These mandates will also result in higher costs and other unintended consequences.

Researchers identified signs of poor endothelial function and inflammation in overweight/obese children. “The results of the study reinforce the seriousness of childhood obesity, showing that it needs to be reversed early on," one specialist said. 

Ziad Ali, MD, explains how coronary computed tomography angiography is creating a major shift in cardiac care.

The company's implantable Barostim device continues to make an impact on patient care. CVRx also shared excitement about the year ahead, pointing to an important new clinical trial.

The American Board of Cardiovascular Medicine is still pushing forward with its efforts to change how cardiologists are certified in the United States. While the group can reapply in the future for a standalone cardiology board, it is also looking at possible partnerships with other organizations.

Researchers see potential for this technology to make cardiac screening much easier for physicians who are not trained cardiologists.

Patients with this specific subtype of severe aortic stenosis, which can sometimes be challenging to diagnose, face a number of additional risks.

The January employment situation summary, released Feb. 11 by the Bureau of Labor Statistics, shows an American economy leaning heavily on healthcare to put jobseekers to work. 

Developed by Novocure, the portable Optune Pax system uses tumor treating fields aimed directly at the site of the cancer to disrupt cell reproduction. A Phase 3 clinical trial shows it improves survival by two months on average versus chemotherapy alone.